https://synergypublishers.com/pms/index.php/gjgh <div class="entry"> <h3>Global Journal of Gastroenterology &amp; Hepatology (GJGH) has ceased publication and is no longer accepting submissions.</h3> <h3>All previously published articles are available in the archive of the journal.</h3> <div class="clear"> </div> </div> en-US Thu, 11 Feb 2021 00:00:00 +0000 OJS 3.3.0.10 http://blogs.law.harvard.edu/tech/rss 60 https://synergypublishers.com/pms/index.php/gjgh/article/view/1915 Pseudo-sclerodermas are neglected dermatological conditions associated with metabolic dysfunction of phenylalanine. Phenylalanine metabolic disorder is an autosomal genetic mutation in phenylalanine hydrolase (PAH). This mutation results in phenylalanine metabolism deficiency and subsequent accumulation of phenylalanine and phenylpyruvic acid in the blood and the cutaneous tissues. The accumulation induces several systemic complications including neurological and dermatological disorders. This report focuses on the mechanisms underlying the induction of the dermatological disorders, current advances in the treatment of phenylketonuria (PKU), and the prospective research areas of interest for the management of dermatological abnormalities in PKU. This metabolic disorder induces chronic bleeding, cellulitis, dermatitis, eczema, psoriasis and parapsoriasis, benign neoplasms of the skin, and melanomas of the skin causing dysregulation of immune cells. The infiltration of CD4+ T-cells and macrophages stimulates IL-4, IL-10, IL-13, and IL-17 leading to the destruction of cutaneous tissues. The insufficiencies of phenylalanine hydroxylase (PAH) and dihydrobiopterin reductase (DHPR) in PKU leads to the accumulation of phenylalanine and phenylpyruvic acid in the corium of the skin. The neurological and psychosocial manifestations of PKU have attracted current advances in therapeutic management targeting the correction of the enzymatic defects in the metabolic pathways or immunoregulation underlying inflammatory conditions to improve the quality of life in PKU patients. However, there is a knowledge gap on the effectiveness of the current therapeutic advance to restore variations in dermatological abnormalities in PKU. Further studies on comorbidities, etiologies, environmental exposures, psychosocial and social effects, and the effects of new therapeutic strategies would provide an insight into the management of pseudo-sclerodermas in PKU disorders. Kwame Kumi Asare1, Justice Afrifa2 and Yeboah Kwaku Opoku3 1Department of Biomedical Sciences, School of Allied health Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana; 2Department of Medical Laboratory Science, University of Cape Coast, Cape Coast, Ghana; 3Department of Biology Education, Faculty of Science Education, University of Education, Winneba, Ghana Copyright (c) https://synergypublishers.com/pms/index.php/gjgh/article/view/1915 Thu, 11 Feb 2021 00:00:00 +0000 https://synergypublishers.com/pms/index.php/gjgh/article/view/1916 The occurrence of ocular palsies in the course of herpes zoster opthalmicus (HZO) is a rare but severe complication. The oculomotorius nerve is most commonly involved, whereas there are only a few published cases reporting paralysis of the abducens nerve. We describe the case of a 55-year-old woman who developed a sixth nerve palsy a few days after appearance of a painful skin lesions on the right side of her forehead. Polymerase chain reaction (PCR) was positive for VZV. The patient was treated with intravenous acyclovir. 6 months after initial manifestation, the patient still had a partial palsy of the abducens nerve. Tamara Quint, Christian Jantschitsch and Harald Maier Department of Dermatology, Medical University of Vienna, Vienna, Austria Copyright (c) https://synergypublishers.com/pms/index.php/gjgh/article/view/1916 Thu, 11 Feb 2021 00:00:00 +0000